Anaemia management in patients with chronic kidney disease: A position statement by the Anaemia Working Group of European Renal Best Practice (ERBP)

Nephrology Dialysis Transplantation

Volumn 24, Issue 2, 2009, Pages 348-354

  Locatelli, Francesco ^a   Covic, Adrian ^b   Eckardt, Kai Uwe ^c   Wiecek, Andrzej ^d   Vanholder, Raymond ^e  

^a A MANZONI HOSPITAL   (Italy)

^b C I PARHON NATIONAL INSTITUTE OF ENDOCRINOLOGY   (Romania)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d MEDICAL UNIVERSITY OF SILESIA   (Poland)

^e GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Anaemia; Biosimilars; Erythropoiesis stimulating agents; Guidelines; Pure red cell aplasia

Indexed keywords

ANTIANEMIC AGENT; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; EPOETIN ZETA; FERRIC GLUCONATE; HEMOGLOBIN; HX 575; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ANEMIA; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG APPROVAL; HUMAN; IRON THERAPY; MEDICAL SOCIETY; META ANALYSIS; MULTICENTER STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PURE RED CELL ANEMIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; REVIEW; SYSTEMATIC REVIEW;

ANEMIA; BLOOD TRANSFUSION; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; IRON; MALE; NEOPLASMS; RED-CELL APLASIA, PURE; RENAL INSUFFICIENCY, CHRONIC;

EID: 58649094413     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn653     Document Type: Review

References (48)

1. Eknoyan G, Lameire N, Barsoum R et al. The burden of kidney disease: improving global outcomes. Kidney Int 2004; 66: 1310-1314
2. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006; 47(5 Suppl 3): S16-18
3. KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease, 2007 update of hemoglobin target. Am J Kidney Dis 2007; 50(3): 471-530
4. Locatelli F, Aljama P, Bárány P et al. European Best Practice Guidelines Working Group. Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19(Suppl 2): ii1-47
5. Zoccali C, Abramowicz D, Cannata-Andia JB et al. European Best Practice Guidelines; European renal best practice. European best practice quo vadis? From European Best Practice Guidelines (EBPG) to European Renal Best Practice (ERBP). Nephrol Dial Transplant 2008; 23: 2162-2166
6. National Kidney Foundation. K/DOQI Clinical Practice Guidelines. 2000 update. Am J Kidney Dis 2001; 37(Suppl 1): S1-S238
7. Anaemia Work Group for National Kidney Foundation-Dialysis Outcomes Quality Initiative (NKF-DOQI). Clinical practice guidelines for the treatment of anaemia of chronic renal failure. Am J Kidney Dis 1997; 30(Suppl 3): 192-240
8. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590
9. Strippoli GF, Craig JC, Manno C et al. Hemoglobin targets for the anemia of chronic kidney disease: a meta-analysis of randomized, controlled trials. J Am Soc Nephrol 2004; 15: 3154-3165
10. Drueke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Eng J Med 2006; 335: 2071-2084
11. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Eng J Med 2006; 335: 2085-2098
12. Phrommintikul A, Haas SJ, Elsik M et al. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007; 369: 381-388
13. Locatelli F, Nissenson AR, Barrett BJ et al. Clinical practice guidelines for anemia in chronic kidney disease: problems and solutions. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2008; 74(10): 1237-1240
14. Mix TC, Brenner RM, Cooper ME et al. Rationale-Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J 2005; 149: 408-413
15. Besarab A, Goodkin DA, Nissenson AR. Normal hematocrit cardiac trial authors. The normal hematocrit study-follow-up. N Engl J Med 2008; 358: 433-434
16. Szczech LA, Barnhart HX, Inrig JK et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 2008; 74: 791-798
17. Berns JS, Elzein H, Lynn RI et al. Hemoglobin variability in epoetin-treated hemodialysis patients. Kidney Int 2003; 64: 1514-1521
18. Yang W, Israni RK, Brunelli SM et al. Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol 2007; 18: 3164-3170
19. LinksIshani A, Solid CA, Weinhandl ED et al. Association between number of months below K/DOQI haemoglobin target and risk of hospitalization and death. Nephrol Dial Transplant 2008; 23: 1682-1689
20. Coyne DW, Kapoian T, Suki W et al. DRIVE Study Group. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 2007; 18: 975-984
21. Deicher R, Horl WH. Differentiating factors between erythropoiesis- stimulating agents: a guide to selection for anaemia of chronic kidney disease. Drugs 2004; 64: 499-509
22. Smith WB, Dowell JA, Pratt RD. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease. Clin Ther 2007; 29: 1368-1380
23. Spinowitz BS, Pratt RD, Epoetin Delta 2002 Study Group. Epoetin delta is effective for the management of anaemia associated with chronic kidney disease. Curr Med Res Opin 2006; 22: 2507-2513
24. Martin KJ. The first human cell line-derived erythropoietin, epoetin delta (Dynepo®), in the management of anemia in patients with chronic kidney disease. Clin Nephrol 2007; 68: 26-31
25. Kwan JTC. Subcutaneous epoetin delta for the management of anaemia in patients with CKD: safety and efficacy in a one year study. Poster presented at ASN Renal Week. J Am Soc Nephrol 2006; 17: 187A
26. Kwan JT, Pratt RD The Epoetin Delta Study Group. Epoetin delta, erythropoietin produced in a human cell line, in the management of anaemia in predialysis chronic kidney disease patients. Curr Med Res Opin 2007; 23: 307-311
27. Spinowitz BS. Anemia management in patients on peritoneal dialysis: efficacy and safety of epoetin {delta}. Haematologica 2008; 93: 761-764.
28. Macdougall IC, Eckardt KU. Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia. Lancet 2006; 368: 947-953
29. Macdougall IC, Robson R, Opatrna S et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol 2006; 1: 1211-1215
30. Tsubakihara Y, Bessho M, Suzuki M. Pharmacokinetic (PK) and pharmacodynamic (PD) profiles of intravenous (IV) administrations of C.E.R.A. (continuous erythropoietin receptor activator) in chronic kidney disease (CKD) patients not on dialysis. Nephrol Dial Transplant 2006; 21(Suppl 4): iv150 (Abstract SP406)
31. Jarsch M, Brandt M, Lanzendörfer M et al. Comparative erythropoietin receptor binding kinetics of C.E.R.A. and epoetin-beta determined by surface plasmon resonance and competition binding assay. Pharmacology 2008; 81: 63-69
32. de Francisco AL, Sulowicz W, Klinger M et al. BA16260 Study Investigators. Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II study. Int J Clin Pract 2006; 60: 1687-1696
33. Provenzano R, Besarab A, Macdougall IC et al. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study. Clin Nephrol 2007; 67: 306-317
34. Macdougall IC, Walker R, Provenzano R et al. ARCTOS Study Investigators. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clin J Am Soc Nephrol 2008; 3: 337-347
35. Klinger M, Arias M, Vargemezis V et al. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. Am J Kidney Dis 2007; 50: 989-1000
36. Besarab A, Salifu MO, Lunde NM et al. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic kidney disease. Clin Ther 2007; 29: 626-639
37. Locatelli F, Villa G, De Francisco ALM et al. Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis. Curr Med Res Opin 2007; 23: 969-979
38. Canaud B, Mingardi G, Braun J et al. STRIATA Study Investigators. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrol Dial Transplant 2008; 23: 3654-3661
39. Levin NW, Fishbane S, Cañedo FV et al. MAXIMA Study Investigators. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet 2007; 370: 1415-1421
40. Sulowicz W, Locatelli F, Ryckelynck JP et al. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol 2007; 2: 637-646
41. Spinowitz B, Coyne DW, Lok CE et al. RUBRA Study Investigators. C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks. Am J Nephrol 2008; 28: 280-289
42. Casadevall N, Nataf J, Viron B et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002; 346: 469-475
43. Hermeling S, Schellekens H, Crommelin DJ et al. Micelle-associated protein in epoetin formulations: a risk factor for immunogenicity? Pharm Res 2003; 20: 1903-1907
44. Bennett CL, Cournoyer D, Carson KR et al. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood 2005; 106: 3343-3347
45. Eckardt KU, Macdougall IC, Froissart M et al. Successful treatment of anti-erythropoietin antibody-mediated pure red cell aplasia with HematideTM. Nephrol Dial Transplant 2008; 1(Suppl 2): i216 (abstract)
46. Woodburn KW, Fan Q, Winslow S et al. Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model. Exp Hematol 2007; 35: 1201-1208
47. FDA Briefing Document. Safety Concerns Associated with Aranesp (darbepoetin alfa) Amgen, Inc. and Procrit (epoetin alfa) Ortho Biotech, L.P., for the Treatment of Anemia Associated with Cancer Chemotherapy: Hearings before the Subcommittee on Oncologic Drugs Advisory Committee, Center for Drug Evaluation and Research. http://www.fda.gov/ohrms/dockets/ac/04/briefing/4037B2- 04- FDA-Aranesp-Procrit.htm#-ednref45
48. FDA Briefing Document. 10 May 2007: Oncologic Drugs Advisory Committee. Continuing reassessment of the risks of erythropoiesis-stimulating agents (ESAs) administered for the treatment of anemia associated with cancer chemotherapy. http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4301b2-02-FDA.pdf